Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AXT-1004
- Development stage
- Preclinical
- Lead developer
- Axter Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AXT-1004 is a preclinical-stage small molecule inhibitor developed by Axter Therapeutics. It is designed to target Pan-MLL (Mixed Lineage Leukemia) proteins, which are frequently involved in chromosomal translocations that drive aggressive forms of leukemia and certain solid tumors. By inhibiting the MLL complex, AXT-1004 aims to disrupt the epigenetic dysregulation that promotes oncogenic gene expression. The drug is currently being investigated for the treatment of hematologic malignancies and various solid tumors.
02
Targets
Histone-lysine N-methyltransferase 2 family (Mixed lineage leukemia protein family)KMT2A
Beyond the preview
Go deeper on AXT-1004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AXT-1004.